Skip to main content
SpringerLink
Log in

Osteolytic lesions marker in multiple myeloma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The degradation product of collagen type I carboxy terminal telopeptide (ICTP) represents a new biochemical parameter that reflects the changes in the resorption properties of skeletal system. Affection of the skeleton is one of the most important characteristics of multiple myeloma (MM). We estimated significance of ICTP as osteolysis predictor and overall survival in comparison with standard prognostic parameters β2-microglobulin and C-reactive protein (CRP), in patients with MM. With our results, we have shown significant difference in serum level of ICTP (P = 0.009) between patients with and without osteolysis on conventional radiography. It was proved that ICTP is the most significant predictor of osteolysis (P = 0.09), while CRP is the most significant risk factor for overall survival (P < 0.01). Being highly significant predictor of osteolysis, ICTP can be used for identification of patients with MM who had increased risk for developing osteolytic lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kyle RA. Multiple myeloma, review of 869 cases. Mayo Clin Proc. 1975;50:29–40.

    PubMed  CAS  Google Scholar 

  2. Abilgard N, Brixen K, Eriksen EF, Kristensen JE, Nilsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica. 2004;89:567–77.

    Google Scholar 

  3. Jakob C, Zavirski I, Heider U, et al. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res. 2003;9:3047–51.

    PubMed  CAS  Google Scholar 

  4. Dimopoulos MA, Moulopoulos LA, Datseris I, et al. Imaging of myeloma bone disease-implications for staging, prognosis and follow-up. Acta Oncol. 2000;39:823–7.

    Article  PubMed  CAS  Google Scholar 

  5. Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol. 1999;104:723–9.

    Article  PubMed  CAS  Google Scholar 

  6. Moulopoulos LA, Dimopoulos MA. Magnetic resonance imging of bone marrow in hematologic malignancis. Blood. 1997;90:2127–47.

    PubMed  CAS  Google Scholar 

  7. Abilgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol. 2000;64:124–9.

    Google Scholar 

  8. Abilgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: eleveted pretreatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haem. 2003;120:235–42.

    Article  Google Scholar 

  9. Batallie R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event of pathogenesis of human multiple myeloma. J Clin Invest. 1991;88:62–6.

    Article  Google Scholar 

  10. Batallie R, Chappard D, Marcelli C, et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol. 1990;76:484–7.

    Article  Google Scholar 

  11. Dizdar O, Barista I, Umut K, et al. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Haemat. 2007;82:185–91.

    Article  CAS  Google Scholar 

  12. Abilgaard N, Bentzen S, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Br J Haem. 1997;96:103–10.

    Article  Google Scholar 

  13. Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem. 1997;30:573–93.

    Article  PubMed  CAS  Google Scholar 

  14. Jakob C, Zavrski I, Heider U, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (Ntx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol. 2002;69:37–42.

    Article  PubMed  CAS  Google Scholar 

  15. Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin rations. Eur J Haematol. 1999;62(5):300–6.

    Article  PubMed  CAS  Google Scholar 

  16. Risteli J, Elomas I, Nieml S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone degradation. Clin Chem. 1993;39(4):635–40.

    PubMed  CAS  Google Scholar 

  17. Elmoaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992;66(2):337–41.

    Article  Google Scholar 

  18. Fonseca R, Trendle MC, Leong T, et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol. 2000;109:24–9.

    Article  PubMed  CAS  Google Scholar 

  19. Batallie R, Boccadoro M, Klein B, Durie BG, Pileri A. C-reactive protein and β2-microglobulin produce a simple and powerful myeloma staging sistem. Blood. 1992;80:733–7.

    Google Scholar 

Download references

Acknowledgements

Reagent assets for radioimmunoassay are provided by the Ministry of Science of Republic of Serbia for project number 145018. The authors would like to thank Dr Henry Dushan Atkinson, North London Sports Orthopaedics, SOUK, and North Middlesex University Hospital, Sterling way, London N18 1QX, for his assistance in the preparation of this manuscript.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Author information

Authors and Affiliations

  1. Institute of Hematology, Clinical Center of Serbia, str: Koste Todorovica 2, Belgrade, Serbia

    Irena Djunic, Ivo Elezovic, Nada Suvajdzic-Vukovic, Dragica Tomin, Gradimir Jankovic, Jelena Bila, Darko Antic & Ana Vidovic

  2. Experimental laboratory, Institute of Oncology and Radiology, Belgrade, Serbia

    Milica Marinkovic, Borka Neskovic & Dragica Nikolic-Vukosavljevic

Authors
  1. Irena Djunic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivo Elezovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Milica Marinkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nada Suvajdzic-Vukovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dragica Tomin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gradimir Jankovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jelena Bila
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Darko Antic
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ana Vidovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Borka Neskovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dragica Nikolic-Vukosavljevic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irena Djunic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Djunic, I., Elezovic, I., Marinkovic, M. et al. Osteolytic lesions marker in multiple myeloma. Med Oncol 28, 237–240 (2011). https://doi.org/10.1007/s12032-010-9432-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9432-4

Keywords

Search

Navigation